Best CAR-T CDMOs in Europe

← All CAR-T CDMOs Best Clean FDA History Commercial Scale

Region: USA Europe Asia

CDMOs tracked

Fully scored

With FDA records

FDA inspections

115

EMA/MHRA GMP certs

For European-manufactured car-t programs, Charles River Laboratories, Novartis, and Minaris Advanced Therapies lead CDMO Signal's ranking of car-t CDMOs with confirmed European manufacturing sites. Filtered from the global directory of 31 scored car-t CDMOs to 13 with European facility presence. EU and UK manufacturing carry specific regulatory considerations for sponsors: EMA and MHRA GMP certification — which contribute directly to the Signal Score's Quality Compliance pillar — are typically required for material supplied to EU/UK trials or commercial markets, and Qualified Person (QP) release is a distinct process step that doesn't apply to US-only manufacturing. Rankings update as new inspection and certificate data enters the platform. Full methodology at cdmosignal.com/methodology.

CAR-T CDMOs manufacture engineered T-cell products, combining viral-vector transduction, T-cell activation and expansion, and rapid release testing — usually as autologous, per-patient batches on tight vein-to-vein timelines.

Choosing a CAR-T CDMO depends on autologous vs allogeneic experience, in-house vs sourced vector, closed-system processing, and chain-of-identity logistics, alongside a clean regulatory record. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.

FDA inspection outcomes across these CDMOs: 12 NAI (no action), 12 VAI (voluntary action), 2 OAI (official action). Leading inspection & GMP sites: Austria (42), United States (22), Denmark (18), Germany (11), France (8).

Last updated 2026-07-22. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

#	CDMO	Signal Score	Quality	FDA · GMP	Capacity	Programs
1	CR Charles River Laboratories Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD	91.7	98.7	8 insp · 11 GMP	Limited	0 programs
2	Novartis Basel, Switzerland	88.3	90.9	14 insp · 62 GMP	—	135 programs
3	MN Minaris Advanced Therapies Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP	83.5	100.0	1 insp · 6 GMP	Limited	0 programs
4	SC SCTbio Prague, Czech Republic	81.6	100.0	0 insp · 5 GMP	—	0 programs
5	AG AGC Biologics Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP	80.6	99.9	2 insp · 23 GMP	Available	2 programs
6	CF CELLforCURE (SEQENS) Les Ulis, FR	80.3	100.0	0 insp · 4 GMP	—	0 programs
7	RC RoslinCT Edinburgh, UK · Hopkinton, MA	80.2	98.8	1 insp · 1 GMP	Available	0 programs
8	NV Novartis Contract Manufacturing Morris Plains, NJ · Stein, CH	79.1	90.9	—	Constrained	284 programs
9	OR Ori Biotech London, UK	78.1	100.0	0 insp · 1 GMP	—	0 programs
10	MB Miltenyi Biotec Bergisch Gladbach, Germany	74.6	100.0	0 insp · 2 GMP	—	8 programs
11	CP Cell and Gene Therapy Catapult Stevenage, United Kingdom	59.0	—	—	—	0 programs
12	EX Excellos La Rochelle, France	59.0	—	—	—	0 programs
13	CZ Cellex Cell Professionals Cologne, Germany	59.0	—	—	—	0 programs

How we score CDMOs →

What to evaluate in a CAR-T CDMO

Vector supply

CAR-T needs a lentiviral or retroviral vector. Confirm whether the CDMO produces vector in-house or coordinates a supplier, and how that affects timelines and cost.

Autologous logistics & turnaround

Autologous CAR-T lives or dies on vein-to-vein time and chain-of-identity. Evaluate scheduling, apheresis handling, and cryo-logistics.

Closed, scalable processing

Closed and automated platforms reduce contamination risk and support parallel patient slots. Ask about cleanroom grade and concurrent-batch capacity.

Regulatory track record

Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.

EMA and MHRA regulatory considerations for European-manufactured programs

European manufacturing for biopharma programs typically requires EMA-recognized GMP certification (via the EudraGMDP database) for EU material and MHRA GMP certification for UK material — post-Brexit, these are separate credentials even for CDMOs operating in both. The Signal Score's Quality Compliance pillar weighs EMA + MHRA GMP certificate density directly, so European CDMOs with dense certification typically rank higher on this pillar. Sponsors should verify certificate coverage for the specific manufacturing activity (drug substance vs drug product, dosage form) at the specific facility being considered — GMP certificates are activity-scoped, not blanket.

QP release requirements and how they affect CDMO selection

Every batch of medicinal product supplied to the EU market must be released by a Qualified Person (QP) — a specific regulatory role with statutory responsibility. This adds a process step (and typically a specific QP-service arrangement) that US-only manufacturing does not require. CDMOs with European operations either have in-house QPs (typical for larger diversified players) or coordinate with external QP services. For sponsors running EU trials or supplying EU commercial markets, this is a non-negotiable requirement to plan for. Individual CDMO profile pages capture facility-level detail; QP arrangements specifically are usually confirmed at RFP stage rather than published.

Which European CDMOs also cover FDA (US) regulatory geography?

European CDMOs with US FDA inspection history — indicating US regulatory posture — are candidates for sponsors running programs in both jurisdictions. The Signal Score's Quality Compliance pillar includes FDA inspection classifications, so a European CDMO with a strong FDA record typically ranks higher on that pillar than a European-only competitor. Cross-check with the US region ranking — CDMOs appearing in both rankings have demonstrated regulatory posture across both jurisdictions, which reduces tech-transfer risk for global programs.

CAR-T CDMOs — Frequently Asked Questions

Who are the top CAR-T CDMOs?

By CDMO Signal's independent Signal Score, the top-ranked CAR-T CDMOs include Charles River Laboratories, Novartis, Minaris Advanced Therapies. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.

How many CAR-T CDMOs have FDA inspection records?

CDMO Signal tracks 5 CAR-T CDMOs with FDA inspection records and 115 EMA/MHRA GMP certificates across the group.

What should I look for in a CAR-T CDMO?

Confirm vector supply (in-house or coordinated), autologous logistics and vein-to-vein turnaround, closed-system scalable processing for parallel patients, and a clean FDA and EMA/MHRA record.

Do CAR-T CDMOs make their own viral vectors?

Some produce lentiviral or retroviral vector in-house; others coordinate an external vector CDMO. In-house vector can shorten timelines and de-risk supply. Check each profile's modality coverage above.

Related modalities

Cell Therapy CDMOs Lentiviral Vector CDMOs Gene Editing CDMOs

Other Modalities

AAV Lentiviral Cell Therapy mRNA/LNP Plasmid DNA Biologics Oligo/ASO Adenoviral Gene Editing Exosome Recombinant Proteins ADC